ERBB2 and neoplasm: On the basis of our study, the prognosis for a HER2-low tumor is significantly better than that for a HER2-zero tumor and similar to that for HER2-positive patients receiving targeted therapy, not only in the whole group (despite their relatively different pCR rates) but also in the non-pCR subgroup.